SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Other Non-Current Assets of $255000.0 for Q1 2026, down 3.04% year-over-year from $263000.0 in Q1 2025, and down 0.78% quarter-over-quarter from $257000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other Non-Current Assets for 17 consecutive years, with $255000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 3.04% year-over-year to $255000.0; the TTM figure through Mar 2026 stood at $255000.0 (down 3.04% YoY), while the FY2025 annual figure was $257000.0, down 3.38% from the prior year.
- Other Non-Current Assets eased to $255000.0 in Q1 2026 per SLS's latest filing, from $257000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $554000.0 in Q1 2022 and bottomed at $34000.0 in Q3 2025.
- Historically, Other Non-Current Assets has averaged $313294.1 across 5 years, with a median of $272000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets slumped 88.59% — and 2026, when it dropped 3.04%.
- SELLAS Life Sciences' Other Non-Current Assets stood at $399000.0 in 2022, then plunged by 31.08% to $275000.0 in 2023, then decreased by 3.27% to $266000.0 in 2024, then dropped by 3.38% to $257000.0 in 2025, then fell by 0.78% to $255000.0 in 2026.
- Business Quant data shows SLS's Other Non-Current Assets at $255000.0 in Q1 2026, $257000.0 in Q4 2025, and $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 253,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253,000.00 |
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | 377,000.00 |
| Jun 30, 2023 | 381,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Dec 31, 2022 | 399,000.00 |
| Sep 30, 2022 | 521,000.00 |
| Jun 30, 2022 | 514,000.00 |
| Mar 31, 2022 | 554,000.00 |
| Dec 31, 2021 | 594,000.00 |
| Sep 30, 2021 | 597,000.00 |